Navigation Links
Cord Blood America Posts Letter to Shareholders: New Administration's Potential Enhanced Stem Cell Research Initiative Should Benefit the Company and Its Shareholders
Date:11/13/2008

SANTA MONICA, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that a letter to shareholders from CEO Matthew Schissler has been posted on the Company's website. The letter explains some of the positive scientific and economic implications of the potential enhanced stem cell research initiatives proposed by the new Obama Administration.

On Sunday, November 9, 2008, John Podesta, who is leading President Elect Barack Obama's transition team, told Fox News (http://www.foxnews.com/story/0,2933,449164,00.html):

"We're looking at -- again, in virtually every agency to see where we can move forward, whether that's on energy transformation, on improving health care, on stem cell research.

There's a lot that the president can do using his executive authority without waiting for congressional action, and I think we'll see the president do that ..."

Mr. Schissler commented, "Because of this interview, there seems to be a rejuvenated and heightened awareness to stem cells and the philosophy change that is anticipated from our President Elect. It is my hope that, through a series of communicative letters to shareholders and families alike, that CBAI can provide valuable information from both a macroeconomic perspective, as well as a direct relation to the individual."

"I am often asked the question: 'What does this mean for Cord Blood America?'" Mr. Schissler said. "Families ask us: 'What does this mean for my family, should I store stem cells, what are the differences between embryonic and adult stem cells, and what does the research mean to our medical community and our economy?'"

"We believe the letter that was posted today and which can be accessed at http://www.cordblood-america.com will help answer some of these questions," Cord Blood America's CEO said. "In summary, we believe that an infusion of capital into stem cell research and development will lead to more therapies being commercialized, a higher percentage of families benefiting from these therapies and, subsequently, a higher percentage of families choosing to store stem cells. We believe this is a significant positive for both stem cell companies and our shareholders."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT:

Paul Knopick

E & E Communications

949/707-5365

pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Education Program Spurs Blacks to Take Blood Pressure Meds
2. Documentary Examining Deadly Blood Disorders and Lifesaving Research to Premiere on Discovery Health
3. Over 50 percent of people with high blood pressure unaware they have condition
4. Documentary Examining Deadly Blood Disorders and Lifesaving Research to Premiere on Discovery Health
5. High Blood Fat Levels Tied to Ischemic Stroke Risk
6. Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC
7. New Blood Test Better Identifies Heart Failure Patients in ER
8. Battling Bacteria in the Blood: U-M Researchers Tackle Deadly Infections
9. Blood pressure control inequality linked to deaths among blacks
10. Heart Valves Fashioned From Stem Cells in Umbilical Cord Blood
11. Tumors grow faster without blood-supply promoting molecule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... ... is the deadliest type of skin cancer. Although only about 1 percent of skin cancer ... than 10,000 people are expected to die of melanoma this year. The risk increases with ... the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  Marking its one ... breast and ovarian cancer risk test, Color ... 30 genes that highly impact the most common ... today, the Color Test analyzes hereditary cancer risks ... and uterine cancers. The Color Test is physician ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... Ste phen Schmidt Join the ... software solutions for life sciences, today announced key new leaders have ... insight to a growing business.  This will bolster the company,s safety ... joined ArisGlobal in the position of Vice President - Safety. ...
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
Breaking Medicine Technology: